AccuStem Sciences, Inc. Extends and Broadens Partnership
with Instituto Europeo di
Oncologia (IEO)
Enabling its Strategic Approach to Address Unanswered Clinical
Questions in Early Stage Breast Cancer
-
StemPrintER
outperformed the current market leader, OncotypeDX test, in
stratifying patients according to their risk of breast cancer
recurrence
London, UK and Phoenix, AZ -- July 11, 2023 -- InvestorsHub
NewsWire -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company
dedicated to improving outcomes for patients with cancer, signs
further agreement with the IEO, one of
the most renowned comprehensive cancer centers in Europe. This
important milestone will support the company's strategic
vision following positive results from transATAC study where
StemPrintER assay outperformed the current market leader in risk of
recurrence testing for women with early stage breast
cancer.
With the extension
of the StemPrintER licensing agreement, originally transferred with
all rights and obligations from Tiziana Life Sciences (NASDAQ:
TLSA), AccuStem and the IEO have established and refined goals on
the timing of commercialization and have broadened the number of
regulatory pathways to bring the test to market in the US and
abroad. Beyond this agreement, AccuStem intends to work closely
with the IEO on additional proprietary cancer assays leveraging
StemPrintER technology.
Investigators from
the IEO in Milan and The Royal Marsden Hospital in London evaluated
a subgroup of patients from the prospective, randomized ATAC trial
(TransATAC). The pivotal TransATAC study has been used to evaluate
many of the commonly used breast cancer risk scoring assays,
including the market leading OncotypeDX. This recent analysis
accomplished two important goals for AccuStem's StemPrintER test:
-
Results confirmed
that StemPrintER is highly
prognostic, with high risk patients up to 4 times as likely to
experience a distant recurrence as low risk patients
-
StemPrintER outperformed the
OncotypeDX test, developed by Exact Sciences (NASDAQ: EXAS), in
stratifying patients according to their risk of breast cancer
recurrence[1]
"Showing this
prognostic performance compared to the market leader in a
prospective, randomized trial is a critical milestone for
StemPrintER," said Wendy Blosser, Chief Executive Officer of
AccuStem. "These exciting results are not surprising given the
novel pathways such as tumor "stemness" that StemPrintER
interrogates. We believe that our test will have significant
utility beyond indicating risk of recurrence and aim to demonstrate
that with our future trials. We look forward to our next steps and
leveraging the technology to bring better outcomes to breast cancer
patients"
Breast cancer
remains a significant health challenge worldwide, and despite
advancements in research and treatment options, there are still
unanswered questions regarding the identification, prognosis, and
management of early-stage breast cancer. AccuStem Sciences
recognizes the urgent need to address these gaps in knowledge and
is committed to leveraging its cutting-edge technologies and
expertise in stem cell research to make a meaningful impact in this
field.
AccuStem plans to
launch clinical studies to evaluate StemPrintER's ability to
determine the most effective surgical approach for women with early
stage invasive breast cancer. This could have significant treatment
implications because, beyond clinical factors and patient
preference, clinicians do not currently possess tools to determine
the most appropriate surgical interventions. To demonstrate
StemPrintER's disruptive predictive capabilities in a global market
that sees more than two million new diagnoses each year, AccuStem
will partner with leading US and European institutions to obtain
these clinical data for presentation and publication.
About
AccuStem
AccuStem is a clinical stage
diagnostics company dedicated to optimizing outcomes and quality of
life for all patients with cancer. We plan to drive innovation in
healthcare by offering proprietary molecular testing that addresses
unmet clinical needs from cancer screening through treatment and
monitoring. By interrogating novel disease pathways, such as tumor
"stemness", we believe our tools will help care teams better
understand the biology of each patient's cancer, leading to more
informed decision making. For more information, please
visit www.accustem.com.
About Instituto
Europeo di Oncologia (IEO)
The Instituto Europeo di Oncologia
(IEO) is a leading comprehensive cancer center located in Milan,
Italy. Renowned for its excellence in oncology research and patient
care, IEO is committed to advancing knowledge in the field of
cancer and developing personalized treatment strategies. With a
multidisciplinary approach, IEO brings together internationally
recognized experts to collaborate on groundbreaking research
initiatives, aiming to improve cancer outcomes and quality of life
for patients worldwide.
Forward-Looking
Statements
This press release contains "forward-looking statements"
Forward-looking statements reflect our current view about future
events. When used in this press release, the words "anticipate,"
"believe," "estimate," "expect," "future," "intend," "plan," or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward–looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned.
Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict
all of them. We cannot guarantee future results, levels of
activity, performance or achievements. AccuStem Sciences, Inc.
assumes no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the
date of this release.
Media Contact:
Email: Info@accustem.com
Investor Contact:
Email: investors@accustem.com